4 NEWS
ARE YOUR PATIENTS STILL WAITING FOR ASTHMA CONTROL ?* * TRELEGY ELLIPTA IS INDICATED FOR MAINTENANCE TREATMENT OF ASTHMA IN ADULT PATIENTS NOT ADEQUATELY CONTROLLED ON ICS / LABA 1
Trelegy Ellipta showed superior improvement in lung function ( trough
FEV 1
) vs FF / VI ( ICS / LABA ) * 3
4 NEWS
10 MAY 2024 ausdoc . com . au
Endometriosis drug green-lit
Rachel Fieldhouse A NEW endometriosis treatment |
for Ryeqo for treating moderate and severe endometriosis-related pain . |
|
|
improvement ” in efficacy compared with alendronate . |
dapagliflozin 10mg with sitagliptin 100mg ( Sidapvia ) in conjunction with |
has been given the PBS green light |
This expanded indication was |
Instead of paying $ 400 for a |
metformin if they have had an inad- |
just months after it was approved |
approved by the TGA in late Janu- |
month ’ s supply , most patients will |
equate response to metformin and |
by the TGA . |
ary , allowing doctors to prescribe |
pay $ 31.60 . |
either an SGLT-2 inhibitor or dipepti- |
The once-daily combination pill |
the combined preparation for |
The monoclonal antibody was |
dyl peptidase 4 ( DPP-4 ) inhibitor . |
Ryeqo , which contains the gonado- |
women who have tried other med- |
|
|
recently included in the RACGP ’ s |
The PBAC said it would be “ rea- |
tropin-releasing hormone antagonist |
ications or undergone surgery for |
updated osteoporosis guidance as a |
sonable ” to include Sidapvia in |
relugolix 40mg , oestradiol 1mg and |
endometriosis . |
first-line therapy for postmenopausal |
60-day prescribing and recom- |
norethisterone 0.5mg , was initially |
A PBS listing for romosozumab |
women at very high risk of fractures , |
mended removing restrictions pre- |
indicated for uterine fibroids . |
( Evenity ) for treating severe oste- |
|
|
due to its role in increasing bone for- |
venting doctors from prescribing |
Following its March meeting , |
oporosis in first-line settings was |
mation and reducing bone resorption . |
insulin alongside metformin and |
the PBAC recommended an author- |
also recommended , after the PBAC |
Patients with type 2 diabetes |
fixed dose SGLT-2 inhibitor and DPP4 |
ity required ( streamlined ) listing |
acknowledged its “ significant |
could soon have access to subsidised |
inhibitor treatments . |
ARE YOUR PATIENTS STILL WAITING FOR ASTHMA CONTROL ?* * TRELEGY ELLIPTA IS INDICATED FOR MAINTENANCE TREATMENT OF ASTHMA IN ADULT PATIENTS NOT ADEQUATELY CONTROLLED ON ICS / LABA 1
200 fluticasone furoate / umeclidinium / vilanterol PBS LISTED FOR SEVERE ASTHMA 2
Trelegy Ellipta showed superior improvement in lung function ( trough
FEV 1
) vs FF / VI ( ICS / LABA ) * 3
* Change in trough FEV 1 at 24 weeks ( primary endpoint ): Trelegy Ellipta 200 / 62.5 / 25mcg vs FF / VI 200 / 25mcg 92mL ( 95 % CI 49,135 ), p < 0.0001 ; Trelegy Ellipta 100 / 62.5 / 25mcg vs FF / VI 100 / 25 mcg 110mL ( 95 % CI 66 , 153 ), p < 0.0001 . 3
TRELEGY Ellipta is generally well tolerated . The most commonly reported adverse events were nasopharyngitis , headache and upper respiratory tract infection . 1 , 3 TRELEGY Ellipta 200 PBS listed for severe Asthma 2
Trelegy Ellipta 100 is indicated but not PBS listed for asthma . 1 , 2 FF 100mcg is medium dose and FF 200mcg is high dose ICS . 4
Study design : The CAPTAIN study was a 24-to-52 week , randomised , double-blind , active-controlled , parallel-group , study that evaluated efficacy and safety of TRELEGY Ellipta vs FF / VI in 2436 adult patients whose asthma was inadequately controlled while receiving ICS / LABA . The primary endpoint was mean change from baseline in trough FEV 1 at week 24 . The key secondary endpoint was annualised rate of moderate / severe exacerbations
FEV 1
, forced expiratory volume : FF , fluticasone fuorate ,: ICS , inhaled corticosteroid ; LABA , long-acting beta 2
-agonist: PBS : pharmaceutical benefit scheme :
VI , vilanterol
References : 1 . TRELEGY Ellipta Approved Product Information 2 . www . pbs . gov . au ( accessed on 18th April 2023 ) 3 . Lee et al . Lancet Respir Med 2021 ; 9 : 69-84 4 . National Asthma Council Australia . Australian Asthma Handbook . National Asthma Council Australia , Melbourne , 2023
For more information on GKS products or to report an adverse event involving a GSK product , please contact GSK Medical Information on 1800 033 109 . GlaxoSmithKline Australia Pty Ltd ABN 47 100 162 481 , Melbourne , VIC . Trelegy Ellipta Trade marks are owned by or licensed to the GSK group of companies © 2023 GSK group of companies or its licensor . PM-AU-FVU-ADVT-230002 ( Date of approval : April 2023 )
PBS Information : Severe asthma ( 200 / 62.5 / 25 mcg presentation only ); Authority Required ( Streamlined ). Criteria apply . Refer to PBS for full information .
PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING
Contraindications : Severe milk-protein allergy or hypersensitivity to any of the ingredients . Pregnancy : Category B3 . Dosage : One inhalation once daily . After inhalation , rinse mouth with water without swallowing .
New fears over indemnity
PAGE 2 It added that this represented less than 1 % of their member base , and that Avant ’ s average increases had been below CPI for the last few renewal cycles .
“ Our members are not flagging to us that their premiums may force them to change the way they practise ,” the spokesperson said .
“ Avant looks at the affordability of medical indemnity premiums for our members , and the median premium to billings ratio for our members is less than 3 %.
“ They said when a practitioner has a premium that exceeds 7.5 % of their billings , they were entitled to access the premium support scheme .
‘ If you ’ ve had a claim , it dictates that you will pay higher premiums for the rest of your career .’
However , Dr Bonning said AMA NSW was being approached by doctors saying risk surcharges were being placed on their insurance , which he said he believed sits outside the premium support scheme .
“ Someone might have a $ 20,000 , $ 40,000 or $ 80,000 risk surcharge placed on their practice , and they have to find that cost themselves ,” he said .
“ If you ’ ve had a claim in your career … that dictates that you will pay higher premiums for the rest of your career . If you have two , you ’ ll probably end up with a significant risk surcharge .”